312 related articles for article (PubMed ID: 35157221)
1. COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.
Lee MH; Kim BJ
J Microbiol; 2022 Mar; 60(3):321-334. PubMed ID: 35157221
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
[TBL] [Abstract][Full Text] [Related]
3. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
4. Heterologous immunity induced by 1
Patel RS; Agrawal B
Front Immunol; 2022; 13():952229. PubMed ID: 36045689
[TBL] [Abstract][Full Text] [Related]
5. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
Noor R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
7. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.
Chumakov K; Avidan MS; Benn CS; Bertozzi SM; Blatt L; Chang AY; Jamison DT; Khader SA; Kottilil S; Netea MG; Sparrow A; Gallo RC
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006644
[TBL] [Abstract][Full Text] [Related]
8. New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?
Gupta PK
Cell Immunol; 2020 Oct; 356():104187. PubMed ID: 32745670
[TBL] [Abstract][Full Text] [Related]
9. Vaccines against SARS-CoV-2 variants and future pandemics.
Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS
Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678
[TBL] [Abstract][Full Text] [Related]
10. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
11. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
Sharma D
Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
[TBL] [Abstract][Full Text] [Related]
12. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
13. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
14. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
[TBL] [Abstract][Full Text] [Related]
15. Beyond adaptive immunity: induction of trained immunity by COVID-19 adenoviral vaccines.
Netea MG; Joosten LA
J Clin Invest; 2023 Jan; 133(2):. PubMed ID: 36647822
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
17. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
[TBL] [Abstract][Full Text] [Related]
18. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
[TBL] [Abstract][Full Text] [Related]
19. Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy.
Haque A; Pant AB
J Autoimmun; 2022 Feb; 127():102792. PubMed ID: 34995958
[TBL] [Abstract][Full Text] [Related]
20. The role of trained immunity in COVID-19: Lessons for the next pandemic.
Netea MG; Ziogas A; Benn CS; Giamarellos-Bourboulis EJ; Joosten LAB; Arditi M; Chumakov K; van Crevel R; Gallo R; Aaby P; van der Meer JWM
Cell Host Microbe; 2023 Jun; 31(6):890-901. PubMed ID: 37321172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
